The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection
| Autor: | Reuben-K M Wong, Khek Yu Ho, Khay Guan Yeoh, Leyan Teng, Dede-Selamat Sutedja, Kok-Ann Gwee |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Urea breath test Placebo Severity of Illness Index Gastroenterology Tinidazole Helicobacter Infections law.invention Young Adult Asian People Double-Blind Method Randomized controlled trial law Clarithromycin Internal medicine medicine Clinical endpoint Humans Dyspepsia Intention-to-treat analysis Helicobacter pylori Hepatology biology medicine.diagnostic_test business.industry Heartburn Middle Aged Anti-Ulcer Agents biology.organism_classification Drug Utilization Anti-Bacterial Agents Intention to Treat Analysis Treatment Outcome Gastroesophageal Reflux Drug Therapy Combination Female medicine.symptom business Omeprazole medicine.drug |
| Zdroj: | European Journal of Gastroenterology & Hepatology. 21:417-424 |
| ISSN: | 0954-691X |
| DOI: | 10.1097/meg.0b013e328317b89e |
| Popis: | Objectives/Background The role of Helicobacter pylori infection in functional dyspepsia (FD) remains controversial. Several randomized controlled trials involving populations in the West, observed no statistically significant advantage over placebo. However, none of these studies involved Asian populations which have high infection rates. Methods A double blind, randomized, placebo-controlled trial of H. pylori eradication for FD was conducted in our Singapore-based Asian population. Forty-one patients received active treatment consisting of a 1-week course of omeprazole 20 mg once daily, clarithromycin 250 mg twice daily and tinidazole 500 mg twice daily whereas another 41 patients received matching placebo tablets. A dyspepsia score was derived by grading 5 dyspeptic symptoms on a Likert scale. Symptom assessment and urea breath test were repeated at 6 weeks, 6 and 12 months from the start of treatment. The primary end point was symptom resolution, defined as a dyspepsia score of 0 or 1 at the end of 12 months follow-up. Results On intention-to-treat analyses, symptom resolution was observed in 24% of patients on active treatment and 7% on placebo; the difference in proportion of patients with symptom resolution was statistically significant (P=0.02, 95% confidence interval: 1.1-17.7). H. pylori eradication rates perprotocol and intention-to-treat were 80.0 and 68.3%, on active treatment and 5.6 and 4.9% on placebo (both P values |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|